Treatment of Gastroesophageal Reflux Disease (GERD):
Esomeprazole magnesium delayed-release capsules, USP are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole magnesium delayed-release capsules may be considered.
Esomeprazole magnesium delayed-release capsules are indicated to maintain symptom resolution and healing of erosive esophagitis. Controlled studies do not extend beyond 6 months.
Esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with GERD in adults and children one year or older.
See additional indications below.
|
|
|
|
Mylan Esomeprazole Magnesium Delayed-release Capsules, USP | ||
Dosage Strengths | Mylan NDC | Dosage Forms |
40 mg | 0378-2351-93 0378-2351-10 |
Each capsule contains 44.50 mg of esomeprazole magnesium, equivalent to 40 mg of esomeprazole
|
20 mg | 0378-2350-93 0378-2350-10 |
Each capsule contains 22.25 mg of esomeprazole magnesium, equivalent to 20 mg of esomeprazole
|
The Mylan Blue Bottle™† stands for Mylan quality